Disposition of cannabinoids and their metabolites in serum, oral fluid, sweat patch and urine from healthy individuals treated with pharmaceutical preparations of medical cannabis
- PMID: 33155722
- DOI: 10.1002/ptr.6931
Disposition of cannabinoids and their metabolites in serum, oral fluid, sweat patch and urine from healthy individuals treated with pharmaceutical preparations of medical cannabis
Abstract
Recently, several countries authorized the use of cannabis flowering tops (dried inflorescences) with a standardized amount of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD) and their acidic precursors [Δ-9-tetrahydrocannabinolic acid A (THCA-A) and cannabidiolic acid (CBDA)] to treat neurogenic pain. We studied the acute pharmacological effects and disposition of cannabinoids and their metabolites in serum, oral fluid, sweat patch and urine of 13 healthy individuals treated with medical cannabis decoction and oil. Cannabinoids and their metabolites were quantified by ultrahigh performance tandem mass spectrometry. Even if the oil contained a significantly higher amount of THC, the absorption of THC and its metabolites were similar in both herbal preparations. Conversely, whereas oil contained a significantly higher amount of CBD and a lower amount of CBDA, absorption was significantly higher after decoction intake. Only cannabinoids present in both herbal preparations (THC, CBD, THCA-A and CBDA) were found in oral fluid, due to the higher acidity compared with that of serum. THC metabolites urinary excretion was always higher after decoction administration. Decoction induced greater feeling of hunger and drowsiness than oil preparation. Pharmacokinetics of cannabinoids, their precursors and their metabolites in biological fluids of individuals treated with cannabis decoction and oil showed a high interindividual variability. The aqueous preparation was generally better absorbed than the oil, even if it contained a minor amount of THC, THCA-A and CBD.
Keywords: acute effects; cannabis decoction; cannabis oil; healthy volunteers; medical cannabis; pharmacokinetics.
© 2020 John Wiley & Sons, Ltd.
References
REFERENCES
-
- Baratta, F., Simiele, M., Pignata, I., Ravetto Enri, L., Torta, R., De Luca, A., … Brusa, P. (2019). Development of standard operating protocols for the optimization of cannabis-based formulations for medical purposes. Frontiers in Pharmacology, 10, 701.
-
- Belendiuk, K. A., Baldini, L. L., & Bonn-Miller, M. O. (2015). Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders. Addiction Science & Clinical Practice, 10, 10.
-
- Boehnke, K. F., Scott, J. R., Litinas, E., Sisley, S., Clauw, D. J., Goesling, J., & Williams, D. A. (2019). Cannabis use preferences and decision-making among a cross-sectional cohort of medical cannabis patients with chronic pain. The Journal of Pain, 20(11), 1362-1372.
-
- Brierley, D. I., Samuels, J., Duncan, M., Whalley, B. J., & Williams, C. M. (2016). Neuromotor tolerability and behavioural characterisation of cannabidiolic acid, a phytocannabinoid with therapeutic potential for anticipatory nausea. Psychopharmacology (Berline), 233(2), 243-254.
-
- Carcieri, C., Tomasello, C., Simiele, M., De Nicolò, A., Avataneo, V., Canzoneri, L., … D'Avolio, A. (2018). Cannabinoids concentration variability in cannabis olive oil galenic preparations. Journal of Pharmacy and Pharmacology, 70(1), 143-149.
MeSH terms
Substances
Grants and funding
- FIS PI14/00715/Instituto de Salud Carlos III (ISCIII, FIS-FEDER)
- FIS PI17/019/Instituto de Salud Carlos III (ISCIII, FIS-FEDER)
- PFIS FI18/00179/Instituto de Salud Carlos III (ISCIII, FIS-FEDER)
- FIS PI17/01962/Instituto de Salud Carlos III (ISCIII, FIS-FEDER)
- 2017 SGR 316/AGAUR Gencat Suport Grups Recerca
- 2015I054/Ministerio de Sanidad, Política Social e Igualdad (Plan Nacional Sobre Drogas-PNSD)
- PT17/0017/0016/ISCIII-Plataforma de Unidades de Iinvestigación y Ensayos Clínicos-SCREN
- RD16/0017/0003; Italian Presidence of Ministers Council, Department of Antidrug Policy/ISCIII-Red de Trastornos Adictivos (RTA)
LinkOut - more resources
Full Text Sources
Medical